Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2023-505510-26-00 | Other Identifier | CTIS |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This research aims to assess the interest of preemptive treatment with Acyclovir in mechanically ventilated patients with reactivation of Herpes simplex (HSV) in the throat and failure of one organ or less. HSV reactivation is common in patients hospitalized in an intensive care unit (ICU) on invasive mechanical ventilation. It begins at the oropharyngeal level (incidence up to 20-50%), then progresses downward with contamination of the distal airways (reported incidence of 20-65%). HSV reactivation is associated with high mortality. The investigators aim to disable that, in mechanically ventilated patients with HSV reactivation in the throat and failure of one organ or less, preemptive treatment with Acyclovir may reduce mortality.
To answer the question posed in the research, it is planned to include 246 people hospitalized in intensive care on invasive mechanical ventilation, presenting with HSV reactivation of the throat and one organ failure or less.
Herpes simplex virus (HSV) reactivations are frequent in intensive care unit (ICU) patients receiving invasive mechanical ventilation. HSV reactivation first occurs in the throat (incidence up to 20-50%), then progress through a descending way with HSV reactivation in the lung (incidence reported from 20-65%). In some patients, a true HSV bronchopneumonitis can occur: in a prospective study, Luyt et al. found that 24% of patients ventilated for more than 4 days and having ventilator-associated pneumonia suspicion had HSV bronchopneumonitis. These reactivations have been associated with increased mortality, which could be explained by the virus-induced injury on the lung parenchyma, by the increased rate of bacterial pneumonia associated with viral infection, or by the prolongation of mechanical ventilation induced by the previous factors. However, to date it is still unknown if HSV is really a pathogen with its own morbidity/mortality, or only a bystander (with reactivation occurring preferentially in the most severe patients). The only way to know whether or not HSV reactivation has an attributable mortality is to show that a specific treatment, namely acyclovir, has an impact on mortality. One recent randomized controlled study, the PTH study, found that preemptive acyclovir treatment was not associated with shorter duration of mechanical ventilation, as compared to placebo. However, the 60-day mortality rate of patients having received acyclovir was 22% vs. 33% for patients having received a placebo (delta = 11%, p=0.06). Moreover, in the subgroup of patients with 1 organ failure or less (organ failure being defined as a corresponding organ-SOFA (Sepsis-related Organ Failure Assessment) score of 3 or 4), 60-day mortality was significantly lower in patients receiving acyclovir (9%) than mortality of patients receiving placebo (30%, p =0.004). As mortality was not the primary endpoint of PTH study, these exploratory but promising results have yet to be formally confirmed. Therefore, the investigators aim to demonstrate that, in patients mechanically ventilated with HSV reactivation in the throat and 1 organ failure or less, pre-emptive treatment with acyclovir may decrease mortality.
This study is a multicenter, randomized, double-blind, placebo-controlled, concealed allocation superiority trial of intravenous acyclovir vs. placebo for mechanically ventilated patients with 1 organ failure or less and HSV reactivation in the throat. Patients ventilated >96 hours and without exclusion criteria will be screened twice weekly for HSV reactivation using quantitative PCR on swab collected in the throat.
Patients with HSV reactivation will be included and randomized into 2 groups (1:1): acyclovir or placebo. Patients will receive intravenous acyclovir or placebo during 14 days. To keep the blind design of the study, acyclovir and placebo will be reconstituted and/ diluted before the administration in saline bag by the pharmacy or a research's dedicated person (according to sites' possibilities) and dispensed to clinicians. Study drug will be stopped in patients discharged from ICU before end of treatment, i.e. if the patient is discharged before 14 days post randomization.
Allocation concealment will be centralized using a secure web-based randomization system. Patients will be reviewed daily in ICU, at hospital discharge and/or at day 60 post-randomization. Vital status, nosocomial bacterial and viral infection will be collected from day 1 to ICU discharge or day 60. Vital status will be collected at day 90. If discharged from hospital prior to 90 days, the patient (or substitute decision-maker if unable to communicate) will be contacted by telephone to determine the disposition and vital status.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| ACYCLOVIR | Experimental | Intravenous acyclovir (ACYCLOVIR ) |
|
| PLACEBO | Placebo Comparator | saline bags |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Intravenous acyclovir (ACYCLOVIR ) | Drug | Patients randomized in the experimental arm will receive intravenous acyclovir at a dosing of 5 mg/kg/8 hours during 14 days (treatment will be stopped at ICU discharge). |
| Measure | Description | Time Frame |
|---|---|---|
| Mortality | Primary endpoint will be the mortality at day 60 post randomization | day 60 |
| Measure | Description | Time Frame |
|---|---|---|
| Mortality | Day 90 | Vital status at day 90 will be assessed either by visit if the patient is still in the hospital, or by phone is the patient is discharged from the hospital |
| Duration of mechanical ventilation |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Charles-Edouard LUYT, Pr | Contact | (0)142163824 | +33 | charles-edouard.luyt@aphp.fr |
| Anne BISSERY | Contact | (0)142162432 | +33 |
| Name | Affiliation | Role |
|---|---|---|
| Charles-Edouard LUYT, Pr | Assistance Publique - Hôpitaux de Paris | Principal Investigator |
Not provided
Not provided
| ID | Term |
|---|---|
| D000212 | Acyclovir |
| ID | Term |
|---|---|
| D006147 | Guanine |
| D007042 | Hypoxanthines |
| D011688 | Purinones |
| D011687 | Purines |
| D006574 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Saline bags | Drug | Patients randomized in the control arm will receive placebo, eg. saline bags (same volume as acyclovir bags) every 8 hours during 14 days (treatment will be stopped in case of ICU discharge). |
|
Duration of mechanical ventilation, either invasive or non-invasive, from randomization to extubation or death, whichever first occurs
| from date of randomization until the date of extubation or death, whichever first occurs, up to 60 days |
| Ventilator-free days at day 60 | Measured as the number of day alive and without mechanical ventilation (invasive mechanical ventilation or non-invasive mechanical ventilation) from randomization to day 60 post-randomization. Patients dying before day 60 will have zero ventilator-free days. | day 60 post-randomization |
| ICU length of stay | Measured by the number of day in the ICU from randomization to ICU discharge or death | from date of randomization until the date of ICU discharge or death, up to 60 days |
| ICU-free days | measured as the number of day alive and outside the ICU from randomization to day 60 post-randomization. Patients dying before day 60 will have zero ICU-free days. | day 60 post-randomization |
| Hospital length of stay | Measured by the number of day in the hospital from randomization to hospital discharge or death | from date of randomization until the date of hospital discharge or death, up to 60 days |
| Hospital-free days | Measured as the number of day alive and outside the hospital from randomization to day 60 post-randomization. Patients dying before day 60 will have zero ICU-free days. | Day 60 post randomization |
| Sepsis-related Organ Failure Assessment (SOFA) score (if patient is still hospitalized in ICU) | This score will be collected using measures collected routinely in the ICU (clinical parameters, blood sampling) A score of two or more is associated with a 10% mortality risk in patients with suspected infection. | at days 1, 3, 5, 7, 10, 14, 21 and 28 post-randomization |
| Incidence of HSV oral-labial lesions | at day 28 | Oral-labial lesions suggestive of being due to HSV in patients randomized in the study will be recorded. These lesions will be sampled and samples will be sent to the virology laboratory, looking for HSV using polymerase chain reaction (PCR). |
| Rate patient wth HSV positive in the throat | at days 3, 7, 10, 14, 17, 21 and 28 post randomization |
| Rate of patient with HSV positive in the tracheal aspirate (if patient is still hospitalized in ICU) | HSV viral load will be measure by quantitative PCR in tracheal aspirate at all time points. Samples will be centralized and analyzed in the French national reference center for herpesviridae. | at days 1, 7, 14, 21 and 28 post randomization |
| Rate of HSV bronchopneumonitis | HSV bronchopneumonitis will be defined by clinical signs suggestive of pneumonia, and presence of HSV in bronchoalveolar lavage (BAL) with a virus load > 105 copies/ millions of cells, whether or not patient had bacterial-viral (namely HSV and bacteria) co-infection. | day 60 post randomization |
| Rate of acute respiratory distress syndrome (ARDS) | ARDS will be defined according to Berlin criteria . Patients mechanically ventilated in the ICU have routinely chest X-ray and blood gases analyses, parameters needed to diagnose ARDS. These parameters collected routinely will be used to define ARDS | day 60 post randomization |
| Rate of bacterial ventilator-associated pneumonia | Ventilator-associated pneumonia will be defined as clinical signs suggestive of pneumonia, associated with a positive bacteriological sampling. Episodes of ventilator-associated pneumonia will be collected from randomization to day 60. | day 60 post randomization |
| Rate of bacteremia | Bacteremia will be defined as a single positive blood culture for pathogenic bacteria, or 2 different blood culture yielding the same pathogen for saprophytic bacteria. Frequency and source of bacteremia will be recorded | day 60 post randomization |
| Glasgow coma scale (GCS) (if patient is still hospitalized in ICU) | Score range from 3 (completely unresponsive) to 15 (responsive) ; Lower GCS scores are correlated with higher risk of death | at days 1, 3, 5, 7, 10, and 14 post-randomization. |
| Creatinine clearance (if patient is still hospitalized in ICU) | at days 1, 3, 5, 7, 10, 14, 21 and 28 post randomization |
| Number of patients requiring renal replacement therapy | day 14 post randomization |
| Renal replacement therapy- free days | Measured as the number of day alive and without need for renal replacement therapy from randomization to day 14 post-randomization. Patients dying before day 14 will have zero renal replacement therapy-free days | day 14 post randomization |
| Incidence of adverse event, severe adverse event | Intensity and frequency of adverse event and severe adverse event according to the WHO Toxicity Grading Scale for Determining The Severity of Adverse Events | at days 1, 3, 5, 7, 10, 14, 21 and 28 post randomization |
| Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |